News & Views

  • C.Diff Treatment Completes Successful Clinical Trials

C.Diff Treatment Completes Successful Clinical Trials

Jun 16 2020 Read 963 Times

Second phase clinical trials of a treatment for Clostridium difficile Infection (CDI), discovered at the University of Strathclyde, have been successfully completed having met its targets of safety, efficacy and dose selection. The study, carried out in the US and Canada by Glasgow-based biopharmaceutical company MGB Biopharma, confirmed that the antibacterial treatment MGB-BP-3, has the potential to become the new gold standard, first-line treatment for CDI.

Other compounds related to MGB-BP-3 are now to be investigated in a project led by Strathclyde for their potential to treat COVID-19. The success of MGB-BP-3 in the clinic is very encouraging for this new study.

CDI is a serious and often life-threatening infection of the large intestine and is the most frequent cause of diarrhoea in hospitals and care homes. In the clinical trials, patients with CDI were given MGB-BP-3 twice daily for 10 days, achieving an initial cure and sustained cure of 100% at the optimum dose.

MGB Biopharma licensed the compounds from Strathclyde in 2010.

Professor Colin Suckling, MGB (Minor Groove Binder) compounds inventor at Strathclyde University said: “ The news from MGB Biopharma that a MGB-BP-3, a compound discovered in our chemistry department, successfully cures people of Clostridium difficile infection is exciting and hugely significant, not only for these patients but also for further developments of related compounds from Strathclyde to treat other infectious diseases.

“The Strathclyde Minor Groove Binder (S-MGB) project, from which MGB-BP-3 comes, was devised to tackle a wide range of infectious diseases and we have evidence that other compounds in the series are effective in models of fungal and parasitic diseases for which there are no good treatments currently. We are also starting a project to investigate the potential of S-MBGs to tackle COVID-19 supported by the Chief Scientist Office, Scotland and led by my colleague Dr Fraser Scott.

“MGB Biopharma has done an extraordinary job to develop our compound this far and we look forward to further progress together with our excellent academic colleagues at the University of Glasgow and University of Manchester.”

Reader comments

Do you like or dislike what you have read? Why not post a comment to tell others / the manufacturer and our Editor what you think. To leave comments please complete the form below. Providing the content is approved, your comment will be on screen in less than 24 hours. Leaving comments on product information and articles can assist with future editorial and article content. Post questions, thoughts or simply whether you like the content.

Post a Comment

Digital Edition

Lab Asia August 2020

August 2020

In This Edition Chromatography - Measurement of Pesticides in Cannabis sativa and Hemp Matrices - Biphenyl Modified Silica Stabilised by Bulky Substituents - Wettable Phase for Analytical a...

View all digital editions


SIAF Guangzhou - NEW DATES

Aug 11 2020 Guanghzou, China

IE Expo China 2020 - NEW DATES

Aug 13 2020 Shanghai, China

ACS National Meeting & Expo, Fall 2020

Aug 16 2020 San Francisco, CA, USA

Chemspec India 2020 - CANCELLED

Aug 19 2020 Mumbai, India

View all events